Now I have a comprehensive picture. Let me pull together the full year and Q4 2025 numbers for comparison and check the FY guidance figures once more before writing.# Insulet Corporation (PODD) — Q2 2026 Earnings Preview
Report date: Wednesday, August 5, 2026, before market open | Call: 2026Q2 Earnings Call Last close: ~$167 | 52-week range: ~$142 – $352 (stock down roughly 42% over the past year)
Insulet goes into this print in an unusually fragile spot for a company with a long history of ~20%+ growth. Shares have been cut nearly in half since last fall, and even the Q1 beat-and-raise in May failed to hold — the stock still fell sharply on the print, underscoring how sensitive the market has become to any imperfection. Ahead of Wednesday's report, Wall Street is modeling adjusted EPS of roughly $1.38–$1.47 (vs. $1.17 a year ago) and revenue near $803 million, with full-year 2026 consensus EPS around $6.45, up almost 30% year-over-year. Sell-side sentiment remains structurally bullish (a "Strong Buy" consensus, ~19 of 26 analysts at Strong Buy) with price targets well above current levels, but targets have been cut meaningfully in recent months as the quality narrative has overshadowed the growth story.
Insulet's first quarter was, on the surface, excellent: total revenue grew 34% (30% constant currency), with U.S. Omnipod revenue up 28% and international up 45% constant currency, and adjusted EPS grew about 40% to $1.42. Management raised full-year total company revenue growth guidance from 20-22% to 21-23%. The company flagged greater-than-normal Q1 seasonality tied to deductible resets that briefly slowed new customer starts, but said momentum improved through the quarter and into April.
For Q2 specifically, guidance calls for total company revenue growth of 20-22%, Omnipod revenue growth of 21-23%, U.S. Omnipod growth of 18-20%, and international Omnipod growth of 28-30% — a deceleration from Q1's pace, partly explained by a roughly $10 million shift of distributor orders into Q1 (a ~200bp Q2 headwind) and a much tougher prior-year comp (U.S. grew 29% in Q2 2025). Investors should watch whether Insulet beats this range as it has historically, and whether full-year guidance gets reaffirmed, raised, or trimmed — particularly given costs tied to the quality issues discussed below.
This is the crux of the investment debate heading into the print. Insulet initiated a first voluntary correction in March 2026 for specific Omnipod 5 pod lots due to a tubing tear risk, which management estimated at roughly $30 million in total cost, more than half in 2026. That episode already dented Q1 gross margin, with warranty and inventory obsolescence costs contributing to a 240 basis point year-over-year gross margin decline in the quarter.
Then, after the Q1 call, a second and much larger correction followed on May 26, 2026 — this one covering Omnipod 5, DASH, and the legacy Eros system, across the U.S. and international markets, due to a cannula tear issue that could cause insulin under-delivery. Insulet disclosed that approximately 7 million pods were within scope of this action, representing about 8.5% of 2025 global pod production, and that there had been 24 reports of serious adverse events globally, including hospitalizations and diabetic ketoacidosis, though no deaths. The stock fell sharply again on this news, and coverage since has framed quality control — not growth — as the dominant near-term investor concern, noting the recalls put "quality and safety... front and center as near term drivers, potentially crowding out" the growth catalysts investors used to focus on.
Litigation follow-through: Multiple securities class-action law firms have since filed or announced suits against Insulet covering a class period from February 21, 2025 through May 26, 2026, alleging the company failed to disclose deficiencies in manufacturing controls at its Acton, Massachusetts facility that created a foreseeable risk of the corrections that followed. The lead plaintiff deadline is August 31, 2026 — meaning this litigation will remain an overhang through and beyond the print, and investors should listen for any commentary or reserve-related disclosures on the call.
What to listen for: updated cost estimates tied to both corrections, any gross margin/E&O guidance changes, evidence (or absence) of customer/prescriber confidence impact on new customer starts and retention, and any additional field actions. Notably, on a June ADA-conference interview, Insulet's own medical leadership said clinician and patient reaction to the corrections had been fairly muted, with providers more focused on new algorithm features than on the recalls — a data point management will likely lean on to argue the reputational impact has been limited.
Insulet has held effectively 100% share of tubeless insulin pumps, but that is poised to change. Tandem Diabetes is developing a tubeless "Mobi Tubeless" pump, targeting FDA clearance in the second half of 2026 with a phased commercial rollout, and Beta Bionics is developing a tubeless "Mint" patch pump expected around 2027. Insulet's leadership has consistently argued that manufacturing tubeless, disposable devices at scale is extraordinarily difficult (calling it a "graveyard" of failed competitor attempts) and that new entrants will expand the overall AID category rather than simply take share, pointing to MDI-to-AID conversion rates rising from ~60% to ~80% over the past four years as evidence the category — not just Insulet — is growing. Given the timing (Tandem's clearance could land in H2 2026), expect analysts to press management on competitive response, pricing discipline in the pharmacy channel, and durability of Insulet's ~90%+ U.S. coverage position.
Full-year 2026 guidance embedded roughly 100 basis points of adjusted operating margin expansion, funded by top-line growth and gross margin gains, offset by a step-up in R&D (funding Omnipod 6 and the type 2 closed-loop system) and continued sales-force expansion. Adjusted EPS growth of "more than 25%" for 2026 was reaffirmed as of the Q1 call, alongside roughly flat free cash flow versus 2025 due to ramping capital expenditures for manufacturing expansion in Costa Rica, Malaysia, and Acton. On capital return, Insulet repurchased $300 million of stock via accelerated share repurchase in Q1 alone, and the board extended its buyback authorization to December 2027 with an incremental $350 million approved — a signal of confidence that may be tested if litigation or recall costs escalate.
Insulet remains a share-gaining, high-growth, high-margin story in a large underpenetrated market, and the sell-side consensus still expects another EPS beat this week. But two manufacturing-related medical device corrections within three months, resulting securities litigation, and the approach of real tubeless competition have shifted the market's focus from "how fast can they grow" to "can they execute cleanly." Wednesday's report and, especially, management's tone on quality systems, cost impact, and demand resilience will likely matter more to the stock than the headline growth print itself.